"","X","Column1","study","year","psy_or_med","active_type","control_type","descr_active","descr_control","instrument","instrument_name","instrument_value","rating","baseline_mean_active","baseline_sd_active","baseline_n_active","baseline_mean_control","baseline_sd_control","baseline_n_control","post_mean_active","post_sd_active","post_n_active","post_mean_control","post_sd_control","post_n_control","active_mean_change","active_sd_change","active_n_change","control_mean_change","control_sd_change","control_n_change","response_criterion","observed_responders_active","observed_responders_active_n","observed_resp_rate_active","observed_responders_control","observed_responders_control_n","observed_resp_rate_control","responders_active","responders_control","resp_rate_active","resp_rate_control","resp_rate_active_completers","resp_rate_control_completers","responders_active_30","responders_control_30","responders_active_35","responders_control_35","...1","percent_women","cuij_responders_active","cuij_responders_control","time_weeks","comorbid_mental","comorbid_mental.","country","age_group","age_m_active","age_sd_active","age_m_control","age_sd_control","age_m_overall","age_sd_overall","active_percent_women","control_percent_women","diagnosis","no_sites","Notes","comorbid_mental?","cohens_d_active","cohens_d_control","study_ID"
"1",NA,1,"Ackerson, 1998","1998",1,"cbt","wl","cbt","wlc","ham-d","hamd",2,"clinician",19.9,5.5,12,21,5,10,8.8,5.3,12,20.5,3.4,10,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,7,0,0.583333333333333,0,0.583333333333333,0,NA,NA,NA,NA,1,64,7,0.2,NA,"n",NA,"us",NA,15.97,1.43,15.89,0.86,NA,NA,NA,NA,"cut",NA,NA,NA,-2.05555555555555,-0.119047619047619,"Ackerson, 1998_cbt_wlc"
"2",NA,4,"Arnarson, 2009","2009",1,"cbt","cau","cbt","cau","DSM",NA,99,"clinician",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,4,51,NA,NA,NA,"n",NA,"eu",NA,NA,NA,NA,NA,14.5,NA,NA,NA,"sub",NA,NA,NA,NA,NA,"Arnarson, 2009_cbt_cau"
"3",NA,5,"Asarnow, 2002","2002",1,"cbt","wl","cbt + family education","wlc","cdi","cdi",5,"self-report",NA,NA,NA,NA,NA,NA,9.54,7.1,12,12.33,10.56,11,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,5,65,NA,NA,NA,"n",NA,"us",NA,NA,NA,NA,NA,NA,NA,NA,NA,"cut",NA,NA,NA,NA,NA,"Asarnow, 2002_cbt + family education_wlc"
"4",3,3,"Atkinson","2014",0,"Duloxetine","Placebo",NA,NA,"CDRS-R","cdrs",1,"clinician",59.2,10.5,117,60.2,11.7,103,35,NA,87,35,NA,87,NA,NA,NA,NA,NA,NA,"50% improvement on CDRS",NA,NA,0.67,NA,NA,0.62,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,10,"n",NA,"USA","7 to 17",13.1,3,13.3,3.1,NA,NA,54.7,49.5,"mdd","65",NA,NA,NA,NA,"Atkinson_2014_Duloxetine_Placebo"
"5",4,4,"Atkinson","2014",0,"Fluoxetine","Placebo",NA,NA,"CDRS-R","cdrs",1,"clinician",58.8,10.6,117,60.2,11.7,103,35.6,NA,91,35,NA,87,NA,NA,NA,NA,NA,NA,"50% improvement on CDRS",NA,NA,0.63,NA,NA,0.62,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,10,"n",NA,"USA","7 to 17",13.1,3.3,13.3,3.1,NA,NA,52.1,49.5,"mdd","65",NA,NA,NA,NA,"Atkinson_2014_Fluoxetine_Placebo"
"6",70,70,"Atkinson","2018",0,"Desvenlafaxine (high dose)","Placebo",NA,NA,"CDRS","cdrs",1,"clinician",58.45,9.45,121,57.28,8.94,119,NA,NA,NA,NA,NA,NA,-24.4,12.1,121,-22.9,12,119,"missing",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,8,"y","ADHD, self-injurious behaviour, insomnia","USA, Chile","7 to 17",12.87,3.01,13.15,2.68,NA,NA,62.81,50,"mdd","42",NA,NA,NA,NA,"Atkinson_2018_Desvenlafaxine (high dose)_Placebo"
"7",72,72,"Atkinson","2018",0,"Desvenlafaxine (low dose)","Placebo",NA,NA,"CDRS","cdrs",1,"clinician",58.52,9.18,122,57.28,8.94,119,NA,NA,NA,NA,NA,NA,-23.7,12.05,120,-22.9,12,119,"missing",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,8,"y","ADHD, self-injurious behaviour, insomnia","USA, Chile","7 to 17",13.07,2.8,13.15,2.68,NA,NA,56.56,50,"mdd","42",NA,NA,NA,NA,"Atkinson_2018_Desvenlafaxine (low dose)_Placebo"
"8",5,5,"Berard","2006",0,"Paroxetine","Placebo",NA,NA,"MADRS","madrs",3,"clinician",25.9,6.75,182,25.9,5.79,93,NA,NA,177,NA,NA,177,-13.6,10.91,177,-12.8,10.3,91,"50% improvement from baseline",107,177,0.604519774011299,53,91,0.582417582417582,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,12,"y","Anxiety disorders (specific phobia, separation anxiety disorder, panic disorder, social phobia, GAD) and ADHD","International (Belgium, Italy, Spain, UK< The Netherlands, Canada, South Africa, UAE, Argentina, Mexico)","12 to 19",15.5,1.6,15.8,1.6,NA,NA,67,67,"mdd","33",NA,NA,NA,NA,"Berard_2006_Paroxetine_Placebo"
"9",NA,7,"Bolton, 2007","2007",1,"ipt","other ctr","ipt","creative play","Acholi Psychosocial Assessment Instrument (APAI): a local instrument","apai",99,"clinician",43.5,10.1,105,44.2,11.2,105,27.8,17.2,105,40.6,15.7,105,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,32,21,0.304761904761905,0.2,0.304761904761905,0.2,NA,NA,NA,NA,7,57,NA,NA,NA,"n",NA,"other",NA,15,1.1,14.7,1,NA,NA,NA,NA,"cut",NA,NA,NA,-1.15018315018315,-0.267657992565056,"Bolton, 2007_ipt_creative play"
"10",NA,6,"Bolton, 2007","2007",1,"ipt","wl","ipt","wlc","Acholi Psychosocial Assessment Instrument (APAI): a local instrument","apai",99,"clinician",43.5,10.1,105,44.2,10.8,104,27.8,17.2,105,37.3,15.9,104,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,33,22,0.314285714285714,0.211538461538462,0.314285714285714,0.211538461538462,NA,NA,NA,NA,6,57,39,14,NA,"n",NA,"other",NA,15,1.1,15.2,1.2,NA,NA,NA,NA,"cut",NA,NA,NA,-1.15018315018315,-0.51685393258427,"Bolton, 2007_ipt_wlc"
"11",NA,8,"Brent, 1997","1997",1,"cbt","cau","cbt","individual nondirective supportive therapy (NST)","bdi","bdi",4,"self-report",24.3,8.1,37,25.7,7.8,35,5.7,8.6,35,NA,NA,24,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,8,51.9,NA,NA,NA,"n",NA,"us",NA,15.7,1.3,15.7,1.5,15.6,NA,NA,NA,"mdd",NA,NA,NA,-2.22754491017964,NA,"Brent, 1997_cbt_individual nondirective supportive therapy (NST)"
"12",NA,9,"Brent, 1997","1997",1,"other psy","cau","systemic behavior family therapy","individual nondirective supportive therapy (NST)","bdi","bdi",4,"self-report",22.6,8.2,35,25.7,7.8,35,9.1,9.1,29,NA,NA,24,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,9,78.6,NA,NA,NA,"n",NA,"us",NA,15.4,1.4,15.7,1.5,15.6,NA,NA,NA,"mdd",NA,NA,NA,-1.5606936416185,NA,"Brent, 1997_systemic behavior family therapy_individual nondirective supportive therapy (NST)"
"13",9,9,"Bristol-Myers Squibb","2002a",0,"Nefazodone","Placebo",NA,NA,"CDRS","cdrs",1,"clinician",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,-25.8,NA,NA,-22.1,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,8,"missing","missing","USA","missing",NA,NA,NA,NA,NA,NA,NA,NA,"mdd","15",NA,NA,NA,NA,"Bristol-Myers Squibb_2002a_Nefazodone_Placebo"
"14",12,12,"Bristol-Myers Squibb","2002b",0,"Nefazodone","Placebo",NA,NA,"CDRS","cdrs",1,"clinician",61.2,NA,90,58.3,NA,93,NA,NA,NA,NA,NA,NA,-23.2,NA,90,-21.6,NA,93,"missing",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,8,"missing","missing","USA","missing",NA,NA,NA,NA,NA,NA,NA,NA,"mdd","15",NA,NA,NA,NA,"Bristol-Myers Squibb_2002b_Nefazodone_Placebo"
"15",NA,11,"Charkhandeh, 2016","2016",1,"cbt","other ctr","cbt","Reiki","cdi","cdi",5,"self-report",29.46,5.47,65,30,5.37,63,19.94,5.59,65,26.33,5.88,63,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,13,2,0.2,0.0317460317460317,0.2,0.0317460317460317,NA,NA,NA,NA,11,54,NA,NA,NA,"n",NA,"oth",NA,NA,NA,NA,NA,15.26,NA,NA,NA,"mdd",NA,NA,NA,-1.72151898734177,-0.652444444444445,"Charkhandeh, 2016_cbt_Reiki"
"16",NA,10,"Charkhandeh, 2016","2016",1,"cbt","wl","cbt","wlc","cdi","cdi",5,"self-report",29.46,5.47,65,30.35,5.45,60,19.94,5.59,65,30.38,4.66,60,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,16,0,0.246153846153846,0,0.246153846153846,0,NA,NA,NA,NA,10,54,11,0.2,NA,"n",NA,"oth",NA,NA,NA,NA,NA,15.26,NA,NA,NA,"mdd",NA,NA,NA,-1.72151898734177,0.00593471810088973,"Charkhandeh, 2016_cbt_wlc"
"17",NA,13,"Clarke, 1995","1995",1,"cbt","cau","cbt+cau","cau","ham-d","hamd",2,"clinician",3.55,3.2,55,3.86,3.1,70,1.87,2.5,52,2.91,4.3,68,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,20,25,0.363636363636364,0.357142857142857,0.384615384615385,0.367647058823529,NA,NA,NA,NA,13,7,25,28,NA,"n",NA,"us",NA,NA,NA,NA,NA,15.3,0.7,NA,NA,"sub",NA,NA,NA,-0.589473684210526,-0.256756756756757,"Clarke, 1995_cbt+cau_cau"
"18",NA,17,"Clarke, 1999","1999",1,"cbt","wl","cbt + parenting group","wlc","ham-d","hamd",2,"clinician",15.1,6,32,14.5,5.9,27,6.7,7.1,32,7.7,7,27,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,16,18,0.5,0.666666666666667,0.5,0.666666666666667,NA,NA,NA,NA,17,71,18,7,NA,"n",NA,"us",NA,NA,NA,NA,NA,16.2,1.3,NA,NA,"mood",NA,NA,NA,-1.2824427480916,-1.05426356589147,"Clarke, 1999_cbt + parenting group_wlc"
"19",NA,14,"Clarke, 1999","1999",1,"cbt","wl","cbt","wlc","ham-d","hamd",2,"clinician",13,5.3,37,14.5,5.9,27,4.6,4.8,37,7.7,7,27,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,24,14,0.648648648648649,0.518518518518518,0.648648648648649,0.518518518518518,NA,NA,NA,NA,14,71,24,7,NA,"n",NA,"us",NA,NA,NA,NA,NA,16.2,1.3,NA,NA,"mood",NA,NA,NA,-1.66336633663366,-1.05426356589147,"Clarke, 1999_cbt_wlc"
"20",NA,21,"Clarke, 2001","2001",1,"cbt","cau","cbt + cau","cau","ham-d","hamd",2,"clinician",3.2,3.4,45,3.1,3.2,49,1.8,2.1,45,2.9,4.6,49,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,22,15,0.488888888888889,0.306122448979592,0.488888888888889,0.306122448979592,NA,NA,NA,NA,21,64,18,18,NA,"n",NA,"us",NA,14.4,1.4,14.7,1.5,NA,NA,NA,NA,"sub",NA,NA,NA,-0.509090909090909,-0.0512820512820513,"Clarke, 2001_cbt + cau_cau"
"21",NA,24,"Clarke, 2002","2002",1,"cbt","cau","cbt + cau","cau","ham-d","hamd",2,"clinician",12,5.3,41,11.4,5,47,5.5,5.2,41,6,5.1,47,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,23,22,0.560975609756098,0.468085106382979,0.560975609756098,0.468085106382979,NA,NA,NA,NA,24,69,22,22,NA,"n",NA,"us",NA,15.2,1.3,15.3,1.3,NA,NA,NA,NA,"mood",NA,NA,NA,-1.23809523809524,-1.06930693069307,"Clarke, 2002_cbt + cau_cau"
"22",NA,27,"De Cuyper, 2004","2004",1,"cbt","wl","cbt","wlc","cdi","cdi",5,"self-report",12.67,6,9,15.27,4.54,11,10.11,6.03,9,11.73,5.66,11,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,4,3,0.444444444444444,0.272727272727273,0.444444444444444,0.272727272727273,NA,NA,NA,NA,26,75,2,3,NA,"n",NA,"eu",NA,NA,NA,NA,NA,10,NA,NA,NA,"sub",NA,NA,NA,-0.425602660016625,-0.694117647058823,"De Cuyper, 2004_cbt_wlc"
"23",NA,28,"De Jonge-Heesen, 2020","2020",1,"cbt","other ctr","cbt","psychoeducation","cdi","cdi",5,"self-report",16.18,4.92,66,15.68,7.08,64,13.32,7.07,66,14.71,9.06,64,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,14,15,0.212121212121212,0.234375,0.212121212121212,0.234375,NA,NA,NA,NA,27,64,15,14,NA,"n",NA,"eu",NA,NA,NA,NA,NA,13.59,0.68,NA,NA,"cut",NA,NA,NA,-0.477064220183486,-0.120198265179678,"De Jonge-Heesen, 2020_cbt_psychoeducation"
"24",NA,30,"Diamond, 2002","2002",1,"other psy","wl","abft (attachment based family therapy)","wlc","bdi","bdi",4,"self-report",23.8,7.4,16,28,7.1,16,11.8,8.8,16,18.5,11.1,16,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,5,7,0.3125,0.4375,0.3125,0.4375,NA,NA,NA,NA,29,78,9,5,NA,"n",NA,"us",NA,NA,NA,NA,NA,14.9,1.5,NA,NA,"mdd",NA,NA,NA,-1.48148148148148,-1.04395604395604,"Diamond, 2002_abft (attachment based family therapy)_wlc"
"25",NA,31,"Diamond, 2010","2010",1,"other psy","cau","Attachment-Based Family Therapy","enhanced cau","bdi-ii","bdi",4,"self-report",33,9.66,35,33,9.37,31,12.6,13.88,35,18.5,15.91,31,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,21,18,0.6,0.580645161290323,0.6,0.580645161290323,NA,NA,NA,NA,30,83,NA,NA,NA,"y",NA,"us",NA,15.11,1.41,15.29,1.83,NA,NA,NA,NA,"cut",NA,NA,"suicidality",-1.73322005097706,-1.14715189873418,"Diamond, 2010_Attachment-Based Family Therapy_enhanced cau"
"26",76,76,"Durgam","2018",0,"Vilazodone (15mg)","Placebo",NA,NA,"CDRS","cdrs",1,"clinician",57.8,8.7,175,57.5,8.6,171,33.8,12,174,34,12.9,170,-22.9,11.87,174,-22.5,11.73,170,"CDRS ≥40% improvement from baseline",83,174,0.477011494252874,80,170,0.470588235294118,55,56,0.314285714285714,0.327485380116959,0.316091954022989,0.329411764705882,126,116,105,94,NA,NA,NA,NA,8,"missing","missing","USA","12 to 17",14.9,1.6,14.9,1.7,15,NA,58.9,60.2,"mdd","52",NA,NA,-2.31884057971015,-2.18604651162791,"Durgam_2018_Vilazodone (15mg)_Placebo"
"27",74,74,"Durgam","2018",0,"Vilazodone (30mg)","Placebo",NA,NA,"CDRS","cdrs",1,"clinician",56.8,8.5,180,57.5,8.6,171,32.5,11.5,180,34,12.9,170,-24.2,12.07,180,-22.5,11.73,170,"CDRS ≥40% improvement from baseline",103,180,0.572222222222222,80,170,0.470588235294118,67,55,0.372222222222222,0.321637426900585,0.372222222222222,0.323529411764706,131,115,124,113,NA,NA,NA,NA,8,"missing","missing","USA","12 to 17",14.6,1.6,14.9,1.7,15,NA,59.4,60.2,"mdd","52",NA,NA,-2.43,-2.18604651162791,"Durgam_2018_Vilazodone (30mg)_Placebo"
"28",13,13,"Emslie","1997",0,"Fluoxetine","Placebo",NA,NA,"CDRS","cdrs",1,"clinician",58.5,10.5,48,57.6,10.4,48,38.4,14.8,34,47.1,17,26,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,13,4,0.270833333333333,0.0833333333333333,0.382352941176471,0.153846153846154,18,10,16,5,NA,NA,NA,NA,8,"y","Dysthymia, anxiety disordes, ADHD, oppositional/conduct disorder","USA","7 to 17",12.2,2.7,12.5,2.6,NA,NA,46,46,"mdd","1",NA,NA,-1.58893280632411,-0.766423357664234,"Emslie_1997_Fluoxetine_Placebo"
"29",16,16,"Emslie","2002a",0,"Fluoxetine","Placebo",NA,NA,"CDRS","cdrs",1,"clinician",57.1,9.9,109,55.1,11.8,110,35.1,13.5,109,40.2,13.5,105,NA,NA,NA,NA,NA,NA,"30% improvement in CDRS",71,109,0.651376146788991,54,101,0.534653465346535,29,15,0.26605504587156,0.136363636363636,0.26605504587156,0.142857142857143,64,49,63,39,NA,NA,NA,NA,9,"y","ADHD, oppositional defiant disorder, conduct disorder","USA","8 to 17",12.7,2.46,12.69,2.67,NA,NA,49.5,49.5,"mdd","15",NA,NA,-1.88034188034188,-1.17786561264822,"Emslie_2002a_Fluoxetine_Placebo"
"30",19,19,"Emslie","2002b",0,"Nefazodone","Placebo",NA,NA,"CDRS","cdrs",1,"clinician",NA,NA,99,NA,NA,96,NA,NA,99,NA,NA,96,-26.5,NA,99,-22.5,NA,96,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,8,"missing",NA,"USA","12 to 17",NA,NA,NA,NA,NA,NA,NA,NA,"mdd","missing",NA,NA,NA,NA,"Emslie_2002b_Nefazodone_Placebo"
"31",22,22,"Emslie","2006",0,"Paroxetine","Placebo",NA,NA,"CDRS","cdrs",1,"clinician",60.7,9.37,101,62.6,8.96,102,NA,NA,101,NA,NA,100,-22.58,14.77,101,-23.38,16,100,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,8,"y","adhd","USA + Canada","7 to 17",11.9,3,12.1,2.95,12,2.97,46.8,46.8,"mdd","40",NA,NA,NA,NA,"Emslie_2006_Paroxetine_Placebo"
"32",27,27,"Emslie","2007 (combined)",0,"Venlafaxine","Placebo",NA,NA,"HAM-D","hamd",2,"clinician",18.2,5.6,168,18.1,5.6,169,NA,NA,166,NA,NA,162,NA,NA,NA,NA,NA,NA,"50% improvement from baseline score",85,166,0.512048192771084,79,162,0.487654320987654,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,8,"n",NA,"USA","7 to 17",12.2,2.6,12.3,2.6,NA,NA,44,47,"mdd","50",NA,NA,NA,NA,"Emslie_2007 (combined)_Venlafaxine_Placebo"
"33",24,24,"Emslie","2007a",0,"Venlafaxine","Placebo",NA,NA,"CDRS","cdrs",1,"clinician",54.4,NA,80,54.4,NA,85,36.3,13.19,68,38.3,12.82,73,NA,NA,NA,NA,NA,NA,"35% improvement from baseline score",43,68,0.632352941176471,37,73,0.506849315068493,22,13,0.275,0.152941176470588,0.323529411764706,0.178082191780822,44,36,27,24,NA,NA,NA,NA,8,"n",NA,"USA","7 to 17",NA,2.6,NA,2.6,NA,NA,NA,NA,"mdd","50",NA,NA,NA,NA,"Emslie_2007a_Venlafaxine_Placebo"
"34",25,25,"Emslie","2007b",0,"Venlafaxine","Placebo",NA,NA,"CDRS","cdrs",1,"clinician",57.3,NA,102,57.3,NA,94,32.7,13.06,101,34.5,13.43,92,NA,NA,NA,NA,NA,NA,"35% improvement from baseline score",77,101,0.762376237623762,62,92,0.673913043478261,30,29,0.294117647058824,0.308510638297872,0.297029702970297,0.315217391304348,70,67,72,51,NA,NA,NA,NA,8,"n",NA,"USA","7 to 17",NA,2.6,NA,2.6,NA,NA,NA,NA,"mdd","50",NA,NA,NA,NA,"Emslie_2007b_Venlafaxine_Placebo"
"35",28,28,"Emslie","2009",0,"Escitalopram","Placebo",NA,NA,"CDRS","cdrs",1,"clinician",57.6,8.19,154,56,8.27,157,NA,NA,NA,NA,NA,NA,-22.1,15.14,154,-18.8,15.91,157,"40% improvement from baseline score",91,154,0.590909090909091,76,157,0.484076433121019,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,8,"y","ADHD, enuresis, GAD","USA","12 to 17",14.7,1.6,14.5,1.5,NA,NA,59.4,58.6,"mdd","40",NA,NA,NA,NA,"Emslie_2009_Escitalopram_Placebo"
"36",30,30,"Emslie","2014",0,"Duloxetine","Placebo",NA,NA,"CDRS","cdrs",1,"clinician",59.3,10.9,108,58.2,9.4,122,35,NA,105,37.4,NA,117,-23.9,NA,105,-21.6,NA,117,"50% improvement from baseline scores",NA,NA,0.69,NA,NA,0.6,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,10,"n",NA,"USA, Mexico, Canada, Argentina","7 to 17",12.9,2.9,13.1,2.9,NA,NA,55.6,56.6,"mdd","60",NA,NA,NA,NA,"Emslie_2014_Duloxetine_Placebo"
"37",32,32,"Emslie","2014",0,"Fluoxetine","Placebo",NA,NA,"CDRS","cdrs",1,"clinician",57.9,10.1,117,58.2,9.4,122,36.4,NA,112,37.4,NA,117,-22.6,NA,112,-21.6,NA,117,"50% improvement from baseline scores",NA,NA,0.61,NA,NA,0.6,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,10,"n",NA,"USA, Mexico, Canada, Argentina","7 to 17",13,3.2,13.1,2.9,NA,NA,52.1,56.6,"mdd","60",NA,NA,NA,NA,"Emslie_2014_Fluoxetine_Placebo"
"38",NA,34,"Esposito-Smythers, 2019","2019",1,"cbt","cau","cbt","cau","cdi","cdi",5,"self-report",27,8.7,74,26.3,9.8,73,13.2,9.3,64,13.8,9.2,62,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,31,33,0.418918918918919,0.452054794520548,0.484375,0.532258064516129,NA,NA,NA,NA,31,76,25,21,NA,"y",NA,"us",NA,NA,NA,NA,NA,14.91,NA,NA,NA,"mood",NA,NA,"at least one of the following co-occurring riskfactors: a SA prior to the index admission, NSSI, or a substanceuse disorder",-1.53333333333333,-1.31578947368421,"Esposito-Smythers, 2019_cbt_cau"
"39",33,33,"Findling","2009",0,"Fluoxetine","Placebo",NA,NA,"CDRS","cdrs",1,"clinician",53,9.84,18,53.94,9.84,16,34.6,13.66,18,31.31,13.68,16,-18.4,12.47,18,-22.63,12.48,16,"30% improvement from baseline",NA,NA,0.72,NA,16,0.81,5,9,0.277777777777778,0.5625,0.277777777777778,0.5625,10,11,12,9,NA,NA,NA,NA,8,"y","Substance-related disorder, ADHD, PTSD, conduct disorder","USA","12 to 17",16.55,1.11,16.35,1.08,16.46,1.08,22,6,"mdd","1",NA,NA,-1.56595744680851,-1.92431972789116,"Findling_2009_Fluoxetine_Placebo"
"40",86,86,"Findling","2020",0,"Fluoxetine","Placebo",NA,NA,"CDRS","cdrs",1,"clinician",58.1,8.3,97,57.7,9.2,182,34.7,12.8,97,37.8,13.7,182,-22.71,12.8,97,-20.3,1,182,"CDRS ≥40% improvement from baseline",46,84,0.547619047619048,67,155,0.432258064516129,35,41,0.360824742268041,0.225274725274725,0.360824742268041,0.225274725274725,69,96,46,98,NA,NA,NA,NA,8,"y","Learning disorders, ADHD, Communication disorders, oppositional defiant disorder, anxiety disorders","USA, Canada","7 to 17",13.2,2.8,13,2.9,13,NA,52.6,57,"mdd","60",NA,NA,-2.21800947867299,-1.73799126637555,"Findling_2020_Fluoxetine_Placebo"
"41",84,84,"Findling","2020",0,"Vilazodone","Placebo",NA,NA,"CDRS","cdrs",1,"clinician",58.5,9.4,186,57.7,9.2,182,37.2,14.2,186,37.8,13.7,182,-20.7,13.6,186,-20.3,1,182,"CDRS ≥40% improvement from baseline",81,158,0.512658227848101,67,155,0.432258064516129,53,48,0.28494623655914,0.263736263736264,0.28494623655914,0.263736263736264,127,106,102,87,NA,NA,NA,NA,8,"y","Learning disorders, ADHD, Communication disorders, oppositional defiant disorder, anxiety disorders","USA, Canada","7 to 17",13,2.9,13,2.9,13,NA,67.4,57,"mdd","60",NA,NA,-1.80508474576271,-1.73799126637555,"Findling_2020_Vilazodone_Placebo"
"42",98,98,"Forest","2020",0,"Fluoxetine","Placebo",NA,NA,"CDRS","cdrs",1,"clinician",61.5,NA,134,61.1,NA,140,NA,NA,112,NA,NA,118,-24.37,11.85,112,-22.9,11.84,118,"missing",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,8,"n",NA,"USA, Puerto Rico","14 to 17",14.7,1.67,14.3,1.59,14.7,1.67,62.7,69.5,"mdd","49",NA,NA,NA,NA,"Forest_2020_Fluoxetine_Placebo"
"43",96,96,"Forest","2020",0,"Levomilnacipran (40mg)","Placebo",NA,NA,"CDRS","cdrs",1,"clinician",61.8,NA,134,61.1,NA,140,NA,NA,115,NA,NA,118,-23.28,11.9,115,-22.9,11.84,118,"missing",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,8,"n",NA,"USA, Puerto Rico","12 to 17",14.8,1.62,14.3,1.59,14.7,1.67,70.1,69.5,"mdd","49",NA,NA,NA,NA,"Forest_2020_Levomilnacipran (40mg)_Placebo"
"44",97,97,"Forest","2020",0,"Levomilnacipran (80mg)","Placebo",NA,NA,"CDRS","cdrs",1,"clinician",59.4,NA,138,61.1,NA,140,NA,NA,110,NA,NA,118,-22.64,11.74,110,-22.9,11.84,118,"missing",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,8,"n",NA,"USA, Puerto Rico","13 to 17",14.8,1.75,14.3,1.59,14.7,1.67,63,69.5,"mdd","49",NA,NA,NA,NA,"Forest_2020_Levomilnacipran (80mg)_Placebo"
"45",NA,35,"Fristad, 2019","2019",1,"cbt","other ctr","cbt + placebo","placebo","cdrs-r","cdrs",1,"clinician",42,9,19,44,13,18,30,9,18,31,11,18,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2,3,0.105263157894737,0.166666666666667,0.111111111111111,0.166666666666667,NA,NA,NA,NA,32,431,NA,NA,NA,"n",NA,"us",NA,11.7,2.1,11.1,2.4,11.6,2.1,NA,NA,"mood",NA,NA,NA,-1.33333333333333,-1.08333333333333,"Fristad, 2019_cbt + placebo_placebo"
"46",37,37,"Geller","1990",0,"Nortriptyline","Placebo",NA,NA,"CDRS","cdrs",1,"clinician",51.3,4.4,12,52.4,3.7,19,34.7,7.8,12,37.8,9.1,19,NA,NA,NA,NA,NA,NA,"CDRS score of ≤25",1,12,0.0833333333333333,4,19,0.210526315789474,2,1,0.166666666666667,0.0526315789473684,0.166666666666667,0.0526315789473684,7,9,5,4,NA,NA,NA,NA,8,"y","Melancholia, separation anxiety, antisocial behaviour","USA","12 to 17",14,1.7,14.4,1.6,14.3,1.5,75,42.1,"mdd","missing",NA,NA,-2.72131147540984,-2.28125,"Geller_1990_Nortriptyline_Placebo"
"47",38,38,"Geller","1992",0,"Nortriptyline","Placebo",NA,NA,"CDRS","cdrs",1,"clinician",49.9,4.2,26,49.6,4.6,24,32.9,11.4,26,32,9.8,24,NA,NA,NA,NA,NA,NA,"CDRS score of ≤20",8,26,0.307692307692308,4,24,0.166666666666667,6,3,0.230769230769231,0.125,0.230769230769231,0.125,17,13,14,9,NA,NA,NA,NA,8,"n",NA,"USA","6 to 12",9.7,1.6,9.7,1.7,9.7,1.6,26.9,33.3,"mdd","missing",NA,NA,-2.17948717948718,-2.44444444444444,"Geller_1992_Nortriptyline_Placebo"
"48",NA,36,"Gillham, 2006","2006",1,"cbt","cau","cbt","cau","cdi","cdi",5,"self-report",13.19,7.81,147,12.57,7.17,124,11.55,8.21,112,11.37,7.9,104,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,29,23,0.197278911564626,0.185483870967742,0.258928571428571,0.221153846153846,NA,NA,NA,NA,33,53,31,27,NA,"n",NA,"us",NA,NA,NA,NA,NA,11.5,NA,NA,NA,"sub",NA,NA,NA,-0.204744069912609,-0.159256801592568,"Gillham, 2006_cbt_cau"
"49",40,40,"Hughes","1990",0,"Imipramine","Placebo",NA,NA,"CDRS","cdrs",1,"clinician",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"50% reduction in CDRS",4,7,0.571428571428571,1,5,0.2,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,6,"y","Anxiety-related disorders (Group1) and Conduct or oppositional disorders (group2)",NA,"6 to 12",NA,NA,NA,NA,NA,NA,NA,NA,"mdd","missing",NA,NA,NA,NA,"Hughes_1990_Imipramine_Placebo"
"50",NA,37,"Idsoe, 2019","2019",1,"cbt","cau","cbt","cau","ces-d","ces_d",11,"self-report",33.08,9.97,133,32.01,9.75,95,26.85,11.82,133,29.55,10.77,95,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,26,13,0.195488721804511,0.136842105263158,0.195488721804511,0.136842105263158,NA,NA,NA,NA,34,88,25,10,NA,"n",NA,"eu",NA,NA,NA,NA,NA,16.7,1.14,NA,NA,"cut",NA,NA,NA,-0.571821936668196,-0.239766081871345,"Idsoe, 2019_cbt_cau"
"51",NA,38,"Israel, 2013","2013",1,"other psy","cau","abft (attachment based family therapy)","cau","ham-d","hamd",2,"clinician",20.6,4.6,11,19.7,5.5,9,12.5,7.2,11,19.4,5.2,9,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,4,1,0.363636363636364,0.111111111111111,0.363636363636364,0.111111111111111,NA,NA,NA,NA,35,55,4,0.2,NA,"n",NA,"eu",NA,NA,NA,NA,NA,15.6,0.99,NA,NA,"mdd",NA,NA,NA,-1.3728813559322,-0.0560747663551403,"Israel, 2013_abft (attachment based family therapy)_cau"
"52",NA,46,"Kahn, 1990","1990",1,"cbt","other ctr","cbt","Relaxation","cdi","cdi",5,"self-report",31.11,9.58,17,26.94,10.83,17,7.29,66.03,17,12.88,10.71,17,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,10,7,0.588235294117647,0.411764705882353,0.588235294117647,0.411764705882353,NA,NA,NA,NA,43,52,NA,NA,NA,"n",NA,"us",NA,NA,NA,NA,NA,12.1,NA,NA,NA,"mdd",NA,NA,NA,-0.630075386853591,-1.30547818012999,"Kahn, 1990_cbt_Relaxation"
"53",NA,40,"Kahn, 1990","1990",1,"cbt","wl","cbt","wlc","cdi","cdi",5,"self-report",31.11,9.58,17,28.06,9.75,17,7.29,66.03,17,26.94,15.41,17,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,11,1,0.647058823529412,0.0588235294117647,0.647058823529412,0.0588235294117647,NA,NA,NA,NA,37,52,11,3,NA,"n",NA,"us",NA,NA,NA,NA,NA,12.1,NA,NA,NA,"mdd",NA,NA,NA,-0.630075386853591,-0.0890302066772653,"Kahn, 1990_cbt_wlc"
"54",NA,43,"Kahn, 1990","1990",1,"other psy","wl","self-modeling","wlc","cdi","cdi",5,"self-report",27.18,7.84,17,28.06,9.75,17,13.58,7.38,17,26.94,15.41,17,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,6,7,0.352941176470588,0.411764705882353,0.352941176470588,0.411764705882353,NA,NA,NA,NA,40,52,8,3,NA,"n",NA,"us",NA,NA,NA,NA,NA,12.1,NA,NA,NA,"mdd",NA,NA,NA,-1.78712220762155,-0.0890302066772653,"Kahn, 1990_self-modeling_wlc"
"55",45,45,"Keller","2001",0,"Imipramine","Placebo",NA,NA,"HAM-D","hamd",2,"clinician",18.11,4.19,95,18.97,4.1,87,9.2,7.85,94,9.88,7.74,87,NA,NA,NA,NA,NA,NA,"50% improvement from baseline",55,94,0.585106382978723,48,87,0.551724137931034,46,38,0.484210526315789,0.436781609195402,0.48936170212766,0.436781609195402,64,60,60,67,NA,NA,NA,NA,8,"y","Anxiety disorders (e.g. separation anxiety, social anxiety disorder) and externalising disorders","USA + Canada","12 to 18",14.9,1.6,15.1,1.6,NA,NA,58.9,65.5,"mdd","12",NA,NA,-1.48006644518272,-1.53547297297297,"Keller_2001_Imipramine_Placebo"
"56",42,42,"Keller","2001",0,"Paroxetine","Placebo",NA,NA,"HAM-D","hamd",2,"clinician",18.98,4.15,93,18.97,4.1,87,8.24,7.68,90,9.88,7.74,87,NA,NA,NA,NA,NA,NA,"50% improvement from baseline",60,90,0.666666666666667,48,87,0.551724137931034,55,46,0.591397849462366,0.528735632183908,0.611111111111111,0.528735632183908,67,58,57,49,NA,NA,NA,NA,8,"y","Anxiety disorders (e.g. separation anxiety, social anxiety disorder) and externalising disorders","USA + Canada","12 to 18",14.8,1.6,15.1,1.6,NA,NA,62.4,65.5,"mdd","12",NA,NA,-1.81572273879966,-1.53547297297297,"Keller_2001_Paroxetine_Placebo"
"57",48,48,"Klein","1998",0,"Desipramine","Placebo",NA,NA,"HAM-D","hamd",2,"clinician",21.44,3.7,23,21.33,5.2,22,10.23,2.1,18,14.61,2.1,18,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,8,0,0.347826086956522,0,0.444444444444444,0,18,10,18,9,NA,NA,NA,NA,6,"y","Anxiety disorders and behaviour disorders","USA","13 to 18",NA,NA,NA,NA,15.66,1.43,67,67,"mdd","missing",NA,NA,-3.86551724137931,-1.84109589041096,"Klein_1998_Desipramine_Placebo"
"58",51,51,"Kutcher","1994",0,"Desipramine","Placebo",NA,NA,"HAM-D","hamd",2,"clinician",22.63,5.17,30,23.77,5.31,30,12.68,8.68,17,13.42,8.43,25,NA,NA,NA,NA,NA,NA,"50% improvement from baseline",NA,NA,0.48,NA,NA,0.35,9,7,0.3,0.233333333333333,0.529411764705882,0.28,11,14,14,16,NA,NA,NA,NA,6,"n",NA,"Canada","15 to 20",NA,NA,NA,NA,17.8,NA,70,70,"mdd","missing",NA,NA,-1.43682310469314,-1.50655021834061,"Kutcher_1994_Desipramine_Placebo"
"59",55,55,"Kye","1996",0,"Amitriptyline","Placebo",NA,NA,"HAM-D","hamd",2,"clinician",12,4.5,18,13.2,4.1,13,8,4.9,12,8.8,4.5,10,NA,NA,NA,NA,NA,NA,"50% improvement",13,18,0.722222222222222,11,13,0.846153846153846,7,4,0.388888888888889,0.307692307692308,0.583333333333333,0.4,7,9,9,4,NA,NA,NA,NA,8,"n",NA,"USA","12 to 17",14.6,1.8,15.1,2.1,NA,NA,27.7,30.8,"mdd","missing",NA,NA,-0.851063829787234,-1.02325581395349,"Kye_1996_Amitriptyline_Placebo"
"60",90,90,"Le Noury","2015",0,"Imipramine","Placebo",NA,NA,"HAM-D","hamd",2,"clinician",18.1,4.19,95,19,4.1,87,NA,NA,NA,NA,NA,NA,-9,7.85,94,-9.1,0.83,87,"HAM-D score ≤8 or ≥50% improvement",55,94,0.585106382978723,48,87,0.551724137931034,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,8,"y","Anxiety disorder, Oppositional Defiant Disorder, Conduct Disorder, ADHD","USA, Canada","12 to 18",14.9,1.6,15.1,1.6,NA,NA,69.6,52.6,"mdd","12",NA,NA,NA,NA,"Le Noury_2015_Imipramine_Placebo"
"61",88,88,"Le Noury","2015",0,"Paroxetine","Placebo",NA,NA,"HAM-D","hamd",2,"clinician",18.9,4.24,93,19,4.1,87,NA,NA,NA,NA,NA,NA,-10.7,7.68,90,-9.1,0.83,87,"HAM-D score <8 or ≥50% improvement",60,90,0.666666666666667,48,87,0.551724137931034,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,8,"y","Anxiety disorder, Oppositional Defiant Disorder, Conduct Disorder, ADHD","USA, Canada","12 to 18",14.8,1.6,15.1,1.6,NA,NA,60.3,52.6,"mdd","12",NA,NA,NA,NA,"Le Noury_2015_Paroxetine_Placebo"
"62",NA,55,"Lewinsohn, 1990","1990",1,"cbt","wl","cwb adolescents + parents","wlc","bdi","bdi",4,"self-report",21.26,11.35,19,23.84,11.43,19,6.47,8.53,19,20.47,10.28,19,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,12,3,0.631578947368421,0.157894736842105,0.631578947368421,0.157894736842105,NA,NA,NA,NA,50,65,13,4,NA,"n",NA,"us",NA,16.26,1.17,16.28,1.17,NA,NA,NA,NA,"mood",NA,NA,NA,-1.48792756539235,-0.310456011054814,"Lewinsohn, 1990_cwb adolescents + parents_wlc"
"63",NA,52,"Lewinsohn, 1990","1990",1,"cbt","wl","cwb adolescents only","wlc","bdi","bdi",4,"self-report",21.67,11.34,21,23.84,11.43,19,10,11.91,21,20.47,10.28,19,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,9,2,0.428571428571429,0.105263157894737,0.428571428571429,0.105263157894737,NA,NA,NA,NA,47,61,11,4,NA,"n",NA,"us",NA,16.15,0.98,16.28,1.17,NA,NA,NA,NA,"mood",NA,NA,NA,-1.00387096774194,-0.310456011054814,"Lewinsohn, 1990_cwb adolescents only_wlc"
"64",NA,58,"Liddle, 1990","1990",1,"cbt","other ctr","cbt (social competence training)","attention placebo (drama)","cdi","cdi",5,"self-report",21,4.45,11,22.3,4.24,10,14.45,6.74,11,19.3,6.93,10,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,3,1,0.272727272727273,0.1,0.272727272727273,0.1,NA,NA,NA,NA,53,32,NA,NA,NA,"n",NA,"au",NA,NA,NA,NA,NA,9.2,1.15,NA,NA,"cut",NA,NA,NA,-1.17068811438785,-0.53715308863026,"Liddle, 1990_cbt (social competence training)_attention placebo (drama)"
"65",NA,57,"Liddle, 1990","1990",1,"cbt","wl","cbt","wlc","cdi","cdi",5,"self-report",21,4.45,11,20.7,3.34,10,14.45,6.74,11,16.9,6.79,10,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2,1,0.181818181818182,0.1,0.181818181818182,0.1,NA,NA,NA,NA,52,32,3,2,NA,"n",NA,"au",NA,NA,NA,NA,NA,9.2,1.15,NA,NA,"cut",NA,NA,NA,-1.17068811438785,-0.750246791707799,"Liddle, 1990_cbt_wlc"
"66",NA,59,"Listug-Lunde, 2013","2013",1,"cbt","cau","cwd","cau","cdi","cdi",5,"self-report",21,5.29,8,20.37,4.1,8,14.38,9.93,8,13.25,9.87,8,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,3,3,0.375,0.375,0.375,0.375,NA,NA,NA,NA,54,38,3,3,NA,"n",NA,"us",NA,12.38,0.92,12.5,1.07,NA,NA,NA,NA,"cut",NA,NA,NA,-0.869908015768725,-1.01932712956335,"Listug-Lunde, 2013_cwd_cau"
"67",NA,60,"Luby, 2012","2012",1,"other psy","other ctr","PCIT-ED intervention (Parent-Child Interaction Therapy Emotion Development)","psychoeducation","PFCâ€“S","pfc",99,"parent_report",42.8,5.8,25,39.8,10.3,18,30.1,11.3,25,33.7,10.6,18,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,7,2,0.28,0.111111111111111,0.28,0.111111111111111,NA,NA,NA,NA,55,37,NA,NA,NA,"n",NA,"us",NA,4.56,NA,4.06,NA,NA,NA,NA,NA,"mdd",NA,NA,NA,-1.48538011695906,-0.583732057416267,"Luby, 2012_PCIT-ED intervention (Parent-Child Interaction Therapy Emotion Development)_psychoeducation"
"68",82,82,"Lundbeck","2020",0,"Fluoxetine","Placebo",NA,NA,"CDRS","cdrs",1,"clinician",61.8,8.9,150,60.6,9.1,153,NA,NA,NA,NA,NA,NA,-22,14.05,137,-18.2,14.05,137,"CDRS ≥50% improvement",68,137,0.496350364963504,49,137,0.357664233576642,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,12,"y","ADHD, Insomnia, Anxiety disorder, GAD, Social Anxiety Disorder","International (Bulgaria, Canada, Colombia, Estonia, France, Germany, Hungary, Italy, South Korea, Latvia, Mexico, Poland, Russia, Serbia, South Africa, Spain, Ukraine, UK, USA)","12 to 17",14.8,1.6,14.8,1.6,NA,NA,67.3,68.2,"mdd","124",NA,NA,NA,NA,"Lundbeck_2020_Fluoxetine_Placebo"
"69",80,80,"Lundbeck","2020",0,"Vortioxetine (10mg)","Placebo",NA,NA,"CDRS","cdrs",1,"clinician",61.2,9.4,145,60.6,9.1,153,NA,NA,NA,NA,NA,NA,-17.1,14.59,126,-18.2,14.05,137,"CDRS ≥50% improvement",53,126,0.420634920634921,49,137,0.357664233576642,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,12,"y","ADHD, Insomnia, Anxiety disorder, GAD, Social Anxiety Disorder","International (Bulgaria, Canada, Colombia, Estonia, France, Germany, Hungary, Italy, South Korea, Latvia, Mexico, Poland, Russia, Serbia, South Africa, Spain, Ukraine, UK, USA)","12 to 17",14.8,1.66,14.8,1.6,NA,NA,63.3,68.2,"mdd","124",NA,NA,NA,NA,"Lundbeck_2020_Vortioxetine (10mg)_Placebo"
"70",78,78,"Lundbeck","2020",0,"Vortioxetine (20mg)","Placebo",NA,NA,"CDRS","cdrs",1,"clinician",62.5,9.8,159,60.6,9.1,153,NA,NA,NA,NA,NA,NA,-18.9,14.14,139,-18.2,14.05,137,"CDRS ≥50% improvement",60,139,0.431654676258993,49,137,0.357664233576642,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,12,"y","ADHD, Insomnia, Anxiety disorder, GAD, Social Anxiety Disorder","International (Bulgaria, Canada, Colombia, Estonia, France, Germany, Hungary, Italy, South Korea, Latvia, Mexico, Poland, Russia, Serbia, South Africa, Spain, Ukraine, UK, USA)","12 to 17",14.5,1.63,14.8,1.6,NA,NA,59.9,68.2,"mdd","124",NA,NA,NA,NA,"Lundbeck_2020_Vortioxetine (20mg)_Placebo"
"71",NA,62,"Makover, 2019","2019",1,"other psy","cau","The High School Transition Program (HSTP)","cau","smfq","smfq",7,"self-report",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,57,61,NA,NA,NA,"n",NA,"us",NA,NA,NA,NA,NA,13.5,NA,NA,NA,"cut",NA,NA,NA,NA,NA,"Makover, 2019_The High School Transition Program (HSTP)_cau"
"72",NA,63,"March, 2004","2004",1,"cbt",NA,"cbt",NA,"cdrs-r","cdrs",1,"clinician",59.64,4.52,111,NA,NA,NA,42.06,9.18,111,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,12,NA,0.108108108108108,NA,0.108108108108108,NA,NA,NA,NA,NA,58,54,10,NA,NA,"n",NA,"us",NA,NA,NA,NA,NA,14.6,1.5,NA,NA,"mdd",NA,NA,NA,-2.56642335766423,NA,"March, 2004_cbt_NA"
"73",56,56,"March","2004",0,"Fluoxetine","Placebo",NA,NA,"CDRS","cdrs",1,"clinician",58.94,4,109,61.18,4.27,112,36.3,8.18,109,41.77,7.99,112,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,17,12,0.155963302752294,0.107142857142857,0.155963302752294,0.107142857142857,73,53,71,50,NA,NA,NA,NA,12,"y","Anxiety, disruptive behaviour, obsessive-compulsice/tic, substance use, attention-deficit/hyperactivity","USA","12 to 17",NA,NA,NA,NA,14.6,1.5,54.4,54.4,"mdd","13",NA,NA,-3.7175697865353,-3.16639477977161,"March_2004_Fluoxetine_Placebo"
"74",NA,65,"Martinovic, 2006","2006",1,"cbt","cau","cbt","cau","ham-d","hamd",2,"clinician",5.9,0.8,16,5.7,0.7,16,3.3,1.29,15,5.8,1.98,15,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,5,1,0.3125,0.0625,0.333333333333333,0.0666666666666667,NA,NA,NA,NA,60,68,6,1,NA,"n",NA,"eu",NA,NA,NA,NA,NA,17.4,1.6,NA,NA,"sub",NA,NA,NA,-2.48803827751196,0.0746268656716415,"Martinovic, 2006_cbt_cau"
"75",NA,68,"Moeini, 2019","2019",1,"cbt","cau","DAD (Dorehye Amozeshie Dokhtaran)",NA,"ces-d","ces_d",11,"self-report",24.6,11.7,64,22.3,11.8,64,18.5,14,64,21.4,15.6,64,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,22,21,0.34375,0.328125,0.34375,0.328125,NA,NA,NA,NA,63,1,21,16,NA,"n",NA,"other",NA,16.2,0.68,16.5,0.6,NA,NA,NA,NA,"cut",NA,NA,NA,-0.474708171206226,-0.0656934306569345,"Moeini, 2019_DAD (Dorehye Amozeshie Dokhtaran)_NA"
"76",NA,69,"Mufson, 1999","1999",1,"ipt","other ctr","ipt","clinical monitoring","ham-d","hamd",2,"clinician",19.2,7.5,24,18.7,8.6,24,6.3,7.7,24,11.8,8.9,24,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,17,10,0.708333333333333,0.416666666666667,0.708333333333333,0.416666666666667,NA,NA,NA,NA,64,73,16,9,NA,"n",NA,"us",NA,15.7,1.4,15.9,1.7,NA,NA,NA,NA,"mdd",NA,NA,NA,-1.69736842105263,-0.788571428571428,"Mufson, 1999_ipt_clinical monitoring"
"77",NA,71,"Mufson, 2004","2004",1,"ipt","cau","ipt","cau","ham-d","hamd",2,"clinician",18.9,5.9,34,18.3,5,29,8.7,8,34,12.8,8.4,29,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,19,7,0.558823529411765,0.241379310344828,0.558823529411765,0.241379310344828,NA,NA,NA,NA,66,84,18,10,NA,"n",NA,"us",NA,15.3,2.1,14.9,1.7,NA,NA,NA,NA,"mood",NA,NA,NA,-1.46762589928058,-0.82089552238806,"Mufson, 2004_ipt_cau"
"78",1,1,"Organon","2002a",0,"Mirtazapine","Placebo",NA,NA,"CDRS","cdrs",1,"clinician",NA,NA,82,NA,NA,44,35.08,NA,82,37.24,NA,44,NA,NA,NA,NA,NA,NA,"missing",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,8,"n",NA,NA,"7 to 17",12.3,NA,12.4,NA,NA,NA,47.6,56.8,"mdd","17",NA,NA,NA,NA,"Organon_2002a_Mirtazapine_Placebo"
"79",2,2,"Organon","2002b",0,"Mirtazapine","Placebo",NA,NA,"CDRS","cdrs",1,"clinician",NA,NA,88,NA,NA,45,35.39,NA,82,38.76,NA,41,NA,NA,NA,NA,NA,NA,"missing",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,8,"n",NA,NA,"7 to 17",11.9,NA,12.3,NA,NA,NA,50,50.5,"mdd","15",NA,NA,NA,NA,"Organon_2002b_Mirtazapine_Placebo"
"80",59,59,"Paxil (GlaxoSmithKline)","2009",0,"Paroxetine","Placebo",NA,NA,"CDRS","cdrs",1,"clinician",NA,NA,29,NA,NA,27,NA,NA,29,NA,NA,27,-16.5,13.19,29,-11.9,13.2,27,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,8,"n",NA,"Japan","7 to 17",14.4,1.99,14.8,2.62,NA,NA,55.2,66.7,"mdd","33",NA,NA,NA,NA,"Paxil (GlaxoSmithKline)_2009_Paroxetine_Placebo"
"81",NA,73,"Poole, 2017","2017",1,"other psy","cau","Behaviour Exchange Systems Therapy for adolescent depression (BEST MOOD)","supportive parenting program","smfq","smfq",7,"self-report",18.8,1.38,27,17.5,1.35,26,13.23,1.47,25,13.33,1.44,26,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,NA,NA,NA,NA,68,73.4,NA,NA,NA,"n",NA,"au",NA,15,1.3,15.3,1.4,15.2,1.4,NA,NA,"mood",NA,NA,NA,-3.90877192982456,-2.98924731182796,"Poole, 2017_Behaviour Exchange Systems Therapy for adolescent depression (BEST MOOD)_supportive parenting program"
"82",61,61,"Puig-Antich","1987",0,"Imipramine","Placebo",NA,NA,"K-SADS-L","ksads",6,"clinician",3.1,0.43,20,3,0.66,22,1.9,0.68,16,1.9,0.86,22,NA,NA,NA,NA,NA,NA,"Responder: if K-SADS scores in both depressed mood and anhedonia were ≤2. Non-responder: if K-SADS score for at least one of these two key items were ≥3.",9,16,0.5625,15,22,0.681818181818182,6,7,0.3,0.318181818181818,0.375,0.318181818181818,11,13,8,11,NA,NA,NA,NA,5,"n",NA,"USA","missing",9.03,1.58,9.18,1.28,NA,NA,62.5,59,"mdd","33",NA,NA,-2.16216216216216,-1.44736842105263,"Puig-Antich_1987_Imipramine_Placebo"
"83",NA,74,"Reed, 1994","1994",1,"other psy","other ctr","Structured Learning Therapy (SLT)","art and imagery exercises","bdi","bdi",4,"self-report",NA,NA,12,NA,NA,6,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,69,50,NA,NA,NA,"n",NA,"us",NA,NA,NA,NA,NA,NA,NA,NA,NA,"mood",NA,NA,NA,NA,NA,"Reed, 1994_Structured Learning Therapy (SLT)_art and imagery exercises"
"84",NA,79,"Reynolds, 1986","1986",1,"cbt","other ctr","cbt","Relaxation training","bdi","bdi",4,"self-report",21.11,7.75,9,17.09,6.36,11,6.36,3.15,6,5.77,4,8,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,6,6,0.666666666666667,0.545454545454545,1,0.75,NA,NA,NA,NA,74,63,NA,NA,NA,"n",NA,"us",NA,NA,NA,NA,NA,15.65,NA,NA,NA,"cut",NA,NA,NA,-2.70642201834862,-2.18532818532819,"Reynolds, 1986_cbt_Relaxation training"
"85",NA,76,"Reynolds, 1986","1986",1,"cbt","wl","cbt","wlc","bdi","bdi",4,"self-report",21.11,7.75,9,16.9,5.48,10,6.36,3.15,6,18.31,9.82,10,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,5,3,0.555555555555556,0.3,0.833333333333333,0.3,NA,NA,NA,NA,71,63,5,2,NA,"n",NA,"us",NA,NA,NA,NA,NA,15.65,NA,NA,NA,"cut",NA,NA,NA,-2.70642201834862,0.184313725490196,"Reynolds, 1986_cbt_wlc"
"86",NA,83,"Rohde, 2004","2004",1,"cbt","other ctr","cbt","life skills/tutoring","ham-d","hamd",2,"clinician",14.2,5.2,45,6,6.3,48,6,6.3,44,8.3,5.4,47,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,24,4,0.533333333333333,0.0833333333333333,0.545454545454545,0.0851063829787234,NA,NA,NA,NA,78,48,25,8,NA,"y",NA,"us",NA,15.1,1.5,15.1,1.3,15.1,1.4,NA,NA,"mdd",NA,NA,"conduct disorder",-1.42608695652174,0.393162393162393,"Rohde, 2004_cbt_life skills/tutoring"
"87",NA,84,"Rohde, 2014a","2014",1,"cbt","other ctr","cognitive behavioral intervention (CB)","educational brochure control","K-SADS (adapted)","ksads",6,"clinician",1.37,0.35,126,1.38,0.36,124,1.4,0.32,126,1.5,0.41,124,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,1,0,0.00806451612903226,0,0.00806451612903226,NA,NA,NA,NA,79,68,NA,NA,NA,"n",NA,"us",NA,NA,NA,NA,NA,15.5,1.2,NA,NA,"cut",NA,NA,NA,0.0895522388059696,0.311688311688312,"Rohde, 2014a_cognitive behavioral intervention (CB)_educational brochure control"
"88",NA,85,"Rossello, 1999","1999",1,"cbt","wl","cbt","wlc","cdi","cdi",5,"self-report",20.12,6.95,25,20.13,5.99,23,13.28,7.61,21,15.83,6.83,18,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,7,4,0.28,0.173913043478261,0.333333333333333,0.222222222222222,NA,NA,NA,NA,80,54,7,4,NA,"n",NA,"us",NA,NA,NA,NA,NA,14.7,1.4,NA,NA,"mood",NA,NA,NA,-0.93956043956044,-0.670826833073323,"Rossello, 1999_cbt_wlc"
"89",NA,86,"Rossello, 1999","1999",1,"ipt","wl","ipt","wlc","cdi","cdi",5,"self-report",21.21,7.53,23,20.13,5.99,23,10.79,6.51,19,15.83,6.83,18,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,8,3,0.347826086956522,0.130434782608696,0.421052631578947,0.166666666666667,NA,NA,NA,NA,81,54,9,4,NA,"n",NA,"us",NA,NA,NA,NA,NA,14.7,1.4,NA,NA,"mood",NA,NA,NA,-1.48433048433048,-0.670826833073323,"Rossello, 1999_ipt_wlc"
"90",NA,87,"Sanford, 2006","2006",1,"other psy","cau","Family Psychoeducation (FPE) + cau","cau","rads","rads",8,"self-report",NA,NA,16,NA,NA,15,NA,NA,16,NA,NA,15,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,82,65,NA,NA,NA,"n",NA,"can",NA,15.6,1.1,16.1,1.6,NA,NA,NA,NA,"MDD",NA,NA,NA,NA,NA,"Sanford, 2006_Family Psychoeducation (FPE) + cau_cau"
"91",NA,88,"Santomauro, 2016","2016",1,"cbt","wl","cbt","wlc","dass","dass",99,"self-report",24.2,8.97,11,21.6,11.03,12,17.2,8.95,10,23.93,11.58,10,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2,2,0.181818181818182,0.166666666666667,0.2,0.2,NA,NA,NA,NA,83,4,3,1,NA,"y",NA,"au",NA,16,1.33,15.5,1.43,NA,NA,NA,NA,"cut",NA,NA,"ASD",-0.78125,0.20610349402919,"Santomauro, 2016_cbt_wlc"
"92",NA,91,"Shirk, 2014","2014",1,"cbt","cau","m-cbt (modified for interpersonal trauma)","cau","bdi-ii","bdi",4,"self-report",29.85,10.56,20,32.21,12.99,23,21.35,11.62,15,19.38,13.47,20,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2,12,0.1,0.521739130434783,0.133333333333333,0.6,NA,NA,NA,NA,84,83.7,NA,NA,NA,"y",NA,"us",NA,15.25,1.52,15.69,1.55,15.48,1.53,NA,NA,"mood",NA,NA,"at least one incident of interpersonal trauma (physical, sexual or verbal/emotional abuse)",-0.766456266907124,-0.969765684051398,"Shirk, 2014_m-cbt (modified for interpersonal trauma)_cau"
"93",NA,92,"Shomaker, 2016","2016",1,"cbt","other ctr","cbt","psychoeducation","ces-d","ces_d",11,"self-report",25.3,7.3,61,24.5,7.5,58,13.4,NA,61,13.8,NA,58,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,85,100,NA,NA,NA,"n",NA,"us",NA,15,1.6,15.1,1.6,NA,NA,NA,NA,"sub",NA,NA,NA,NA,NA,"Shomaker, 2016_cbt_psychoeducation"
"94",NA,94,"Srivastava, 2020","2020",1,"cbt","cau","cCBT","cau","cdrs-r","cdrs",1,"self-report",67.8,3.1,11,66.9,3.4,10,33.7,11.2,10,45.3,9.7,9,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,3,0,0.272727272727273,0,0.3,0,NA,NA,NA,NA,87,24,NA,NA,NA,"n",NA,"oth",NA,16,1.5,16.1,1.3,16.05,1.5,NA,NA,"mdd",NA,NA,NA,-4.76923076923077,-3.29770992366412,"Srivastava, 2020_cCBT_cau"
"95",NA,95,"Stallard, 2012","2012",1,"cbt","other ctr","cbt","attention control","smfq","smfq",7,"self-report",10.64,4.91,392,10.6,4.67,374,8.22,6.45,296,8.5,5.88,308,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,89,82,0.227040816326531,0.219251336898396,0.300675675675676,0.266233766233766,NA,NA,NA,NA,88,65,NA,NA,NA,"n",NA,"uk",NA,14.3,NA,NA,NA,NA,NA,NA,NA,"cut",NA,NA,NA,-0.426056338028169,-0.398104265402843,"Stallard, 2012_cbt_attention control"
"96",NA,96,"Stallard, 2012","2012",1,"cbt","cau","cbt","cau","smfq","smfq",7,"self-report",10.64,4.91,392,10.56,4.93,298,8.22,6.45,296,6.81,5.7,242,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,102,95,0.260204081632653,0.318791946308725,0.344594594594595,0.392561983471074,NA,NA,NA,NA,89,65,97,90,NA,"n",NA,"uk",NA,14.3,NA,NA,NA,NA,NA,NA,NA,"cut",NA,NA,NA,-0.426056338028169,-0.705550329256821,"Stallard, 2012_cbt_cau"
"97",NA,99,"Stark, 1987","1987",1,"pst","wl","pst","wlc","cdrs-r","cdrs",1,"clinician",33.5,10.27,10,30.33,6.28,9,24.16,6.01,10,28.15,6.21,9,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,NA,NA,NA,NA,92,43,1,0.2,NA,"n",NA,"us",NA,11.1,NA,11.32,NA,11.17,NA,NA,NA,"cut",NA,NA,NA,-1.14742014742015,-0.349079263410729,"Stark, 1987_pst_wlc"
"98",NA,103,"Stark, 1987","1987",1,"other psy","wl","self control","wlc","cdrs-r","cdrs",1,"clinician",37.22,8.36,9,30.33,6.28,9,22.91,4.36,9,28.15,6.21,9,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,NA,NA,NA,NA,96,43,1,0.2,NA,"n",NA,"us",NA,11.2,NA,11.32,NA,11.17,NA,NA,NA,"cut",NA,NA,NA,-2.25,-0.349079263410729,"Stark, 1987_self control_wlc"
"99",NA,107,"Stice, 2008","2008",1,"cbt","cau","cbt based bibliotherapy","assessment only","bdi","bdi",4,"self-report",18.2,7.53,80,19.6,9.23,84,14.25,8.98,80,16.71,9.74,84,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,19,21,0.2375,0.25,0.2375,0.25,NA,NA,NA,NA,100,56,NA,NA,NA,"n",NA,"us",NA,NA,NA,NA,NA,15.6,1.2,NA,NA,"sub",NA,NA,NA,-0.478497880072683,-0.304691618344755,"Stice, 2008_cbt based bibliotherapy_assessment only"
"100",NA,105,"Stice, 2008","2008",1,"cbt","cau","cbt","assessment only","bdi","bdi",4,"self-report",20.03,10.35,89,19.6,9.23,84,10.77,9.04,89,16.71,9.74,84,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,41,22,0.460674157303371,0.261904761904762,0.460674157303371,0.261904761904762,NA,NA,NA,NA,98,56,42,20,NA,"n",NA,"us",NA,NA,NA,NA,NA,15.6,1.2,NA,NA,"sub",NA,NA,NA,-0.95513151108819,-0.304691618344755,"Stice, 2008_cbt_assessment only"
"101",NA,109,"Stice, 2008","2008",1,"sup","cau","sup","assessment only","bdi","bdi",4,"self-report",20.27,9.83,88,19.6,9.23,84,14.67,10.62,88,16.71,9.74,84,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,27,27,0.306818181818182,0.321428571428571,0.306818181818182,0.321428571428571,NA,NA,NA,NA,102,56,30,20,NA,"n",NA,"us",NA,NA,NA,NA,NA,15.6,1.2,NA,NA,"sub",NA,NA,NA,-0.547677261613692,-0.304691618344755,"Stice, 2008_sup_assessment only"
"102",NA,111,"Stikkelbroek, 2020","2020",1,"cbt","cau","cbt","cau","K-SADS","ksads",6,"clinician",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,104,82,NA,NA,NA,"n",NA,"eu",NA,16.9,2.2,16.3,2,16.6,2.1,NA,NA,"mdd",NA,NA,NA,NA,NA,"Stikkelbroek, 2020_cbt_cau"
"103",NA,112,"Szigethy, 2007","2007",1,"cbt","cau","cbt","cau","cdi","cdi",5,"self-report",25.7,10.8,22,21.8,8.1,19,10.7,8,21,16.7,11.1,19,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,11,6,0.5,0.315789473684211,0.523809523809524,0.315789473684211,NA,NA,NA,NA,105,51,13,6,NA,"n",NA,"us",NA,14.95,2.33,15.02,1.83,NA,NA,NA,NA,"sub",NA,NA,NA,-1.59574468085106,-0.53125,"Szigethy, 2007_cbt_cau"
"104",NA,114,"Tang, 2009","2009",1,"ipt","cau","Intensive Interpersonal Psychotherapy for depressed adolescents with suicidal risk (IPT-A-IN)","school-based supportive intervention and psychoeducation","bdi-ii","bdi",4,"self-report",32.66,10.06,35,32.32,8.7,38,19.97,14.68,35,31.58,12.01,38,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,17,3,0.485714285714286,0.0789473684210526,0.485714285714286,0.0789473684210526,NA,NA,NA,NA,107,66,NA,NA,NA,"y",NA,"eas",NA,15.26,1.7,15.24,1.65,NA,NA,NA,NA,"cut",NA,NA,"suicidality",-1.02586903799515,-0.0714630613230325,"Tang, 2009_Intensive Interpersonal Psychotherapy for depressed adolescents with suicidal risk (IPT-A-IN)_school-based supportive intervention and psychoeducation"
"105",NA,115,"Topooco, 2018","2018",1,"cbt","other ctr","cbt","attention control","bdi-ii","bdi",4,"self-report",33.1,9.4,33,32.3,10.2,37,19.9,7.2,33,25.2,7.8,37,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,11,2,0.333333333333333,0.0540540540540541,0.333333333333333,0.0540540540540541,NA,NA,NA,NA,108,94,17,6,NA,"n",NA,"eu",NA,17.2,1,16.9,1.1,NA,NA,NA,NA,"cut",NA,NA,NA,-1.59036144578313,-0.788888888888889,"Topooco, 2018_cbt_attention control"
"106",NA,117,"Topooco, 2019","2019",1,"cbt","other ctr","icbt","minimal attention controlÂ ","bdi","bdi",4,"self-report",31.6,10,35,28.8,7.9,35,16,11.3,31,24.8,10.4,35,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,12,4,0.342857142857143,0.114285714285714,0.387096774193548,0.114285714285714,NA,NA,NA,NA,110,96,NA,NA,NA,"n",NA,"eu",NA,17.5,1.1,17.5,1.2,NA,NA,NA,NA,"cut",NA,NA,NA,-1.46478873239437,-0.437158469945355,"Topooco, 2019_icbt_minimal attention controlÂ "
"107",63,63,"Von Knorring","2006",0,"Citalopram","Placebo",NA,NA,"MADRS","madrs",3,"clinician",30,5.5,124,30,5.5,120,NA,NA,79,NA,NA,74,NA,NA,NA,NA,NA,NA,"50% improvement from baseline",NA,NA,0.61,NA,NA,0.59,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,12,"n",NA,"European, multi-centered (31 recruitment sites)","13 to 18",16,1,16,1,16,1,NA,NA,"mdd","31",NA,NA,NA,NA,"Von Knorring_2006_Citalopram_Placebo"
"108",NA,118,"Vostanis, 1996","1996",1,"cbt","other ctr","cbt","non-focused intervention","mfq","mfq",7,"self-report",33.4,12.2,29,28.6,14.4,28,17.6,5.2,29,18.4,15.8,28,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,15,12,0.517241379310345,0.428571428571429,0.517241379310345,0.428571428571429,NA,NA,NA,NA,111,56,NA,NA,NA,"n",NA,"uk",NA,NA,NA,NA,NA,12.7,NA,NA,NA,"mdd",NA,NA,NA,-1.81609195402299,-0.675496688741722,"Vostanis, 1996_cbt_non-focused intervention"
"109",64,64,"Wagner","2003",0,"Sertraline","Placebo",NA,NA,"CDRS","cdrs",1,"clinician",64.3,11,189,64.6,11,187,NA,NA,185,NA,NA,179,-22.84,NA,NA,-20.19,NA,NA,"40% improvement",128,185,0.691891891891892,106,179,0.592178770949721,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,10,"y","Most common were oppositional defiant disorder, anxiety, adjustment reaction and phobic disorders.","International (USA, India, Canada, Costa Rica, Mexico)","6 to 17",NA,NA,NA,NA,NA,NA,57.1,44.9,"mdd","53",NA,NA,NA,NA,"Wagner_2003_Sertraline_Placebo"
"110",66,66,"Wagner","2004",0,"Citalopram","Placebo",NA,NA,"CDRS","cdrs",1,"clinician",58.8,10.9,89,57.8,11.1,85,NA,NA,89,NA,NA,85,NA,NA,NA,NA,NA,NA,"CDRS score ≤28",32,89,0.359550561797753,20,85,0.235294117647059,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,8,"y","Dysthmia, enuresis","USA","7 to 17",12.1,3.1,12.1,2.8,12.1,NA,52.8,54.1,"mdd","21",NA,NA,NA,NA,"Wagner_2004_Citalopram_Placebo"
"111",68,68,"Wagner","2006",0,"Escitalopram","Placebo",NA,NA,"CDRS","cdrs",1,"clinician",54.5,NA,131,56.6,NA,133,NA,NA,NA,NA,NA,NA,-21.9,NA,129,-20.2,NA,132,"CDRS score ≤28",59,129,0.457364341085271,50,132,0.378787878787879,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,8,"y","Anxiety disorders (e.g. GAD, panic disorder, social phobia, specific phobia)","USA","6 to 17",12.2,2.9,12.4,3,12.3,3,51.9,51.9,"mdd","25",NA,NA,NA,NA,"Wagner_2006_Escitalopram_Placebo"
"112",92,92,"Weihs","2018",0,"Desvenlafaxine","Placebo",NA,NA,"CDRS","cdrs",1,"clinician",56.337,9.585,115,57.06,8.91,112,NA,NA,NA,NA,NA,NA,-22.6,12.547,115,-23.1,12.488,112,"missing",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,8,"y","ADHD, non-suicidal inurious behaviour, insomnia, generalised anxiety disorder, oppositional defiant disorder","USA, Mexico","7 to 17",12.869,1.46,12.65,1.425,NA,NA,55.139,57.5,"mdd","43",NA,NA,NA,NA,"Weihs_2018_Desvenlafaxine_Placebo"
"113",94,94,"Weihs","2018",0,"Fluoxetine","Placebo",NA,NA,"CDRS","cdrs",1,"clinician",56.256,8.34,112,57.06,8.91,112,NA,NA,NA,NA,NA,NA,-24.8,12.382,112,-23.1,12.488,112,"missing",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,8,"y","ADHD, non-suicidal inurious behaviour, insomnia, generalised anxiety disorder, oppositional defiant disorder","USA, Mexico","7 to 17",12.65,1.479,12.65,1.425,NA,NA,50.74,57.5,"mdd","43",NA,NA,NA,NA,"Weihs_2018_Fluoxetine_Placebo"
"114",NA,120,"Weisz, 1997","1997",1,"cbt","cau","cbt","nt","cdrs-r","cdrs",1,"clinician",45.25,16.01,16,38.38,11.15,32,33.19,10.86,16,34.94,10.93,32,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,1,3,0.0625,0.09375,0.0625,0.09375,NA,NA,NA,NA,113,46,3,2,NA,"n",NA,"us",NA,9.4,NA,9.7,NA,9.6,NA,NA,NA,"cut",NA,NA,NA,-0.897655377744697,-0.311594202898551,"Weisz, 1997_cbt_nt"
"115",NA,122,"Weisz, 2009","2009",1,"cbt","cau","cbt","cau","cdi","cdi",5,"self-report",10.88,7.91,32,11.29,7.93,25,8,6.32,25,8.47,8.44,19,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,12,10,0.375,0.4,0.48,0.526315789473684,NA,NA,NA,NA,115,56,NA,NA,NA,"n",NA,"us",NA,NA,NA,NA,NA,11.77,2.14,NA,NA,"mood",NA,NA,NA,-0.404778636683064,-0.344532681734881,"Weisz, 2009_cbt_cau"
"116",NA,124,"Wood, 1996","1996",1,"cbt","other ctr","cbt","relaxing training","mfq","mfq",7,"parent_report",25.8,9.8,24,28.7,11.6,24,14.9,10.4,24,19.8,13.3,24,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,17,15,0.708333333333333,0.625,0.708333333333333,0.625,NA,NA,NA,NA,117,69,NA,NA,NA,"n",NA,"uk",NA,13.8,1.7,14.6,1.6,NA,NA,NA,NA,"mood",NA,NA,NA,-1.07920792079208,-0.714859437751004,"Wood, 1996_cbt_relaxing training"
"117",NA,125,"Young, 2006","2005",1,"ipt","other ctr","ipt","school counseling","ces-d","ces_d",11,"self-report",24.1,6.9,27,27.4,6.6,14,6.4,4.8,27,17.4,10.5,14,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,24,7,0.888888888888889,0.5,0.888888888888889,0.5,NA,NA,NA,NA,118,85,24,5,NA,"n",NA,"us",NA,13.5,1.3,13.1,1.1,13.4,1.2,NA,NA,"cut",NA,NA,NA,-3.02564102564103,-1.16959064327485,"Young, 2006_ipt_school counseling"
"118",NA,127,"Young, 2010","2010",1,"ipt","cau","Interpersonal Psychotherapy-Adolescent Skills Training (IPT-AST)","school counseling","cdrs-r","cdrs",1,"clinician",NA,NA,NA,NA,NA,NA,NA,NA,36,NA,NA,21,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,120,59,NA,NA,NA,"n",NA,"us",NA,14.57,0.68,14.52,0.87,14.51,0.76,NA,NA,"cut",NA,NA,NA,NA,NA,"Young, 2010_Interpersonal Psychotherapy-Adolescent Skills Training (IPT-AST)_school counseling"
"119",NA,128,"Young, 2016","2016",1,"ipt","other ctr","Interpersonal Psychotherapy-Adolescent Skills Training (IPT-AST)","group counselling","ces-d","ces_d",11,"self-report",15.51,8.52,95,15.07,8.65,91,11.12,8.57,93,12.62,9.28,90,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,29,29,0.305263157894737,0.318681318681319,0.311827956989247,0.322222222222222,NA,NA,NA,NA,121,67,38,27,NA,"n",NA,"us",NA,13.56,1.28,13.42,1.18,14.01,1.22,NA,NA,"cut",NA,NA,NA,-0.513750731421884,-0.273284997211378,"Young, 2016_Interpersonal Psychotherapy-Adolescent Skills Training (IPT-AST)_group counselling"
"120",NA,129,"Yu, 2002","2002",1,"cbt","cau","cbt","nt","cdi","cdi",5,"self-report",17.44,9.47,104,16.72,9.29,116,13.64,9.01,101,16.02,10.16,114,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,30,34,0.288461538461538,0.293103448275862,0.297029702970297,0.298245614035088,NA,NA,NA,NA,122,45,30,26,NA,"n",NA,"eas",NA,11.71,1.71,11.99,1.67,11.8,1.69,NA,NA,"cut",NA,NA,NA,-0.411255411255411,-0.0719794344473007,"Yu, 2002_cbt_nt"
